Asymmetric dimethylarginine and diabetes with cerebrovascular diseases
10.3760/cma.j.issn.1673-4165.2010.06.011
- VernacularTitle:非对称性二甲基精氨酸与糖尿病脑血管病变
- Author:
Bo XUE
;
Yuwu ZHAO
- Publication Type:Journal Article
- Keywords:
Arginine;
Nitric oxide synthase;
Nitric oxide;
Diabetes mellitus;
Cerebrovascular disorders;
Arteriosclerosis
- From:
International Journal of Cerebrovascular Diseases
2010;18(6):450-455
- CountryChina
- Language:Chinese
-
Abstract:
Nitric oxide (NO) is the most important known endogenous vasodilator factor. The competitive inhibitor asymmetric dimethylarginine (ADMA) of endothelial nitric oxide synthase (NOS) inhibits NO synthesis, which makes NO/NOS pathway to be obstructed and the reduction of NO synthesis. The studies in recent years have suggested that ADMA is as-sociated with the occurrence and development of diabetes with cerebrovascular disease. It has provided new insights into further clarifying the mechanism of the disease.
